Redox modulation of HMGB1-related signaling

Antioxidants and Redox Signaling

Volumn 20, Issue 7, 2014, Pages 1075-1085

  Janko, Christina ^a   Filipović, Milos ^a   Munoz, Luis E ^a   Schorn, Christine ^a   Schett, Georg ^a   Ivanović Burmazović, Ivana ^a   Herrmann, Martin ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; CYTOKINES; HMGB1 PROTEIN; HUMANS; INFLAMMATION; OXIDATION-REDUCTION; SIGNAL TRANSDUCTION;

EID: 84894038456     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5179     Document Type: Review

References (96)

1. Abdulahad DA, Westra J, Limburg PC, Kallenberg CG, and Bijl M. HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions development. Autoimmun Rev 9: 661-665, 2010.
2. Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z, Buss S, Autschbach F, Pleger ST, Lukic IK, Bea F, Hardt SE, Humpert PM, Bianchi ME, Mairbaurl H, Nawroth PP, Remppis A, Katus HA, and Bierhaus A. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117: 3216-3226, 2008.
3. Batinic-Haberle I, Reboucas JS, and Spasojevic I. Superoxide dismutase mimics: Chemistry, pharmacology, and therapeutic potential. Antioxid Redox Signal 13: 877-918, 2010.
4. Bianchi ME. HMGB1 loves company. J Leukoc Biol 86: 573-576, 2009.
5. Bianchi ME and Agresti A. HMG proteins: Dynamic players in gene regulation and differentiation. Curr Opin Genet Dev 15: 496-506, 2005.
6. Cai B, Deitch EA, and Ulloa L. Novel insights for systemic inflammation in sepsis and hemorrhage. Mediators Inflamm 2010: 642462, 2010.
7. Calvert JW, Elston M, Nicholson CK, Gundewar S, Jha S, Elrod JW, Ramachandran A, and Lefer DJ. Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice. Circulation 122: 11-19, 2010.
8. Carballal S, Trujillo M, Cuevasanta E, Bartesaghi S, Moller MN, Folkes LK, Garcia-Bereguiain MA, Gutierrez-Merino C, Wardman P, Denicola A, Radi R, and Alvarez B. Reactivity of hydrogen sulfide with peroxynitrite and other oxidants of biological interest. Free Radic Biol Med 50: 196-205, 2011.
9. Cary SP, Winger JA, Derbyshire ER, and Marletta MA. Nitric oxide signaling: No longer simply on or off. Trends Biochem Sci 31: 231-239, 2006.
10. Curtin JF, Donovan M, and Cotter TG. Regulation and measurement of oxidative stress in apoptosis. J Immunol Methods 265: 49-72, 2002.
11. Cuzzocrea S, Riley DP, Caputi AP, and Salvemini D. Antioxidant therapy: A new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 53: 135-159, 2001.
12. Dobsak P, Courderot-Masuyer C, Zeller M, Vergely C, Laubriet A, Assem M, Eicher JC, Teyssier JR, Wolf JE, and Rochette L. Antioxidative properties of pyruvate and protection of the ischemic rat heart during cardioplegia. J Cardiovasc Pharmacol 34: 651-659, 1999.
13. Dumitriu IE, Voll RE, Kolowos W, Gaipl US, Heyder P, Kalden JR, and Herrmann M. UV irradiation inhibits ABC transporters via generation of ADP-ribose by concerted action of poly(ADP-ribose) polymerase-1 and glycohydrolase. Cell Death Differ 11: 314-320, 2004.
14. Ellerman JE, Brown CK, De Vera M, Zeh HJ, Billiar T, Rubartelli A, and Lotze MT. Masquerader: High mobility group box-1 and cancer. Clin Cancer Res 13: 2836-2848, 2007.
15. Erlandsson Harris H and Andersson U. Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 34: 1503-1512, 2004.
16. Fan J, Li Y, Levy RM, Fan JJ, Hackam DJ, Vodovotz Y, Yang H, Tracey KJ, Billiar TR, and Wilson MA. Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: Role of HMGB1-TLR4 signaling. J Immunol 178: 6573-6580, 2007.
17. Ferdinandy P and Schulz R. Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 138: 532-543, 2003.
18. Ferrer-Sueta G and Radi R. Chemical biology of peroxynitrite: Kinetics, diffusion, and radicals. ACS Chem Biol 4: 161-177, 2009.
19. Ferrer-Sueta G, Vitturi D, Batinic-Haberle I, Fridovich I, Goldstein S, Czapski G, and Radi R. Reactions of manganese porphyrins with peroxynitrite and carbonate radical anion. J Biol Chem 278: 27432-27438, 2003.
20. Filipovic MR, Duerr K, Mojovic M, Simeunovic V, Zimmermann R, Niketic V, and Ivanovic-Burmazovic I. NO dismutase activity of seven-coordinate manganese(II) pentaazamacrocyclic complexes. Angew Chem Int Ed Engl 47: 8735-8739, 2008.
21. Filipovic MR, Koh AC, Arbault S, Niketic V, Debus A, Schleicher U, Bogdan C, Guille M, Lemaitre F, Amatore C, and Ivanovic-Burmazovic I. Striking inflammation from both sides: Manganese(II) pentaazamacrocyclic SOD mimics act also as nitric oxide dismutases: A single-cell study. Angew Chem Int Ed Engl 49: 4228-4232, 2010.
22. Filipovic MR, Miljkovic J, Allgauer A, Chaurio R, Shubina T, Herrmann M, and Ivanovic-Burmazovic I. Biochemical insight into physiological effects of H(2)S: Reaction with peroxynitrite and formation of a new nitric oxide donor, sulfinyl nitrite. Biochem J 441: 609-621, 2012.
23. Filipovic MR, Stanic D, Raicevic S, Spasic M, and Niketic V. Consequences of MnSOD interactions with nitric oxide: Nitric oxide dismutation and the generation of peroxynitrite and hydrogen peroxide. Free Radic Res 41: 62-72, 2007.
24. Fink MP. Ethyl pyruvate: A novel anti-inflammatory agent. Crit Care Med 31: S51-S56, 2003.
25. Foster MW, Hess DT, and Stamler JS. Protein S-nitrosylation in health and disease: A current perspective. Trends Mol Med 15: 391-404, 2009.
26. Gaillard C, Borde C, Gozlan J, Marechal V, and Strauss F. A high-sensitivity method for detection and measurement of HMGB1 protein concentration by high-Affinity binding to DNA hemicatenanes. PLoS One 3: E2855, 2008.
27. Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME, and Rubartelli A. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 3: 995-1001, 2002.
28. Goodwin GH, Sanders C, and Johns EW. A new group of chromatin-Associated proteins with a high content of acidic and basic amino acids. Eur J Biochem 38: 14-19, 1973.
29. Herrmann M, Zoller OM, Hagenhofer M, Voll R, and Kalden JR. What triggers anti-dsDNA antibodies?. Mol Biol Rep. 23: 265-267, 1996.
30. Hogg N. The biochemistry and physiology of S-nitrosothiols. Annu Rev Pharmacol Toxicol 42: 585-600, 2002.
31. Hoppe G, Talcott KE, Bhattacharya SK, Crabb JW, and Sears JE. Molecular basis for the redox control of nuclear transport of the structural chromatin protein Hmgb1. Exp Cell Res 312: 3526-3538, 2006.
32. Hu X, Cui B, Zhou X, Xu C, Lu Z, and Jiang H. Ethyl pyruvate reduces myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Mol Biol Rep 39: 227-231, 2012.
33. Ivanovic I, Filipovic, and Milos R. Reactivity of manganese superoxide dismutase mimics toward superoxid and nitric oxide: Selectivity versus cross-reactivity. In: Advances in Inorganic Chemistry, Inorganic/Bioinorganic Reaction Mechanisms, edited by Eldik RV. Waltham, Massachusetts: Academic Press, 2012, pp. 53-97.
34. Jang HJ, Kim YM, Tsoyi K, Park EJ, Lee YS, Kim HJ, Lee JH, Joe Y, Chung HT, and Chang KC. Ethyl pyruvate induces heme oxygenase-1 through p38 mitogen-Activated protein kinase activation by depletion of glutathione in RAW 264.7 cells and improves survival in septic animals. Antioxid Redox Signal 17: 878-889, 2012.
35. Janko C, Schorn C, Grossmayer GE, Frey B, Herrmann M, Gaipl US, and Munoz LE. Inflammatory clearance of apoptotic remnants in systemic lupus erythematosus (SLE). Autoimmun Rev 8: 9-12, 2008.
36. Jiang W and Pisetsky DS. Expression of high mobility group protein 1 in the sera of patients and mice with systemic lupus erythematosus. Ann Rheum Dis 67: 727-728, 2008.
37. Jungas T, Verbeke P, Darville T, and Ojcius DM. Cell death, BAX activation, and HMGB1 release during infection with Chlamydia. Microbes Infect 6: 1145-1155, 2004.
38. Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, and Ferguson TA. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of highmobility group box-1 protein. Immunity 29: 21-32, 2008.
39. King AL and Lefer DJ. Cytoprotective actions of hydrogen sulfide in ischaemia-reperfusion injury. Exp Physiol 96: 840-846, 2011.
40. Kurien BT, Hensley K, Bachmann M, and Scofield RH. Oxidatively modified autoantigens in autoimmune diseases. Free Radic Biol Med 41: 549-556, 2006.
41. Lee SY, Jeon HM, Kim CH, Jeong EK, Ju MK, Park SY, Jung SY, Kim YJ, Lim SC, Han SI, and Kang HS. CuZnSOD and MnSOD inhibit metabolic stress-induced necrosis and multicellular tumour spheroid growth. Int J Oncol 37: 195-202, 2010.
42. Leiper J and Nandi M. The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nat Rev Drug Discov 10: 277-291, 2011.
43. Li L, Hsu A, and Moore PK. Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide in the cardiovascular system and in inflammation-A tale of three gases. Pharmacol Ther 123: 386-400, 2009.
44. Limana F, Germani A, Zacheo A, Kajstura J, Di Carlo A, Borsellino G, Leoni O, Palumbo R, Battistini L, Rastaldo R, Muller S, Pompilio G, Anversa P, Bianchi ME, and Capogrossi MC. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit + cell proliferation and differentiation. Circ Res 97: E73-e83, 2005.
45. Lotze MT and Tracey KJ. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 5: 331-342, 2005.
46. Loukili N, Rosenblatt-Velin N, Li J, Clerc S, Pacher P, Feihl F, Waeber B, and Liaudet L. Peroxynitrite induces HMGB1 release by cardiac cells in vitro and HMGB1 upregulation in the infarcted myocardium in vivo. Cardiovasc Res 89: 586-594, 2011.
47. Martinez MC and Andriantsitohaina R. Reactive nitrogen species: Molecular mechanisms and potential significance in health and disease. Antioxid Redox Signal 11: 669-702, 2009.
48. Masini E, Cuzzocrea S, Mazzon E, Marzocca C, Mannaioni PF, and Salvemini D. Protective effects of M40403, a selective superoxide dismutase mimetic, in myocardial ischaemia and reperfusion injury in vivo. Br J Pharmacol 136: 905-917, 2002.
49. Miller YI, Viriyakosol S, Worrall DS, Boullier A, Butler S, and Witztum JL. Toll-like receptor 4-dependent and-independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler Thromb Vasc Biol 25: 1213-1219, 2005.
50. Munoz LE, Janko C, Grossmayer GE, Frey B, Voll RE, Kern P, Kalden JR, Schett G, Fietkau R, Herrmann M, and Gaipl US. Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum 60: 1733-1742, 2009.
51. Munoz LE, Lauber K, Schiller M, Manfredi AA, and Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 6: 280-289, 2010.
52. Mustafa AK, Sikka G, Gazi SK, Steppan J, Jung SM, Bhunia AK, Barodka VM, Gazi FK, Barrow RK, Wang R, Amzel LM, Berkowitz DE, and Snyder SH. Hydrogen sulfide as endothelium-derived hyperpolarizing factor sulfhydrates potassium channels. Circ Res 109: 1259-1268, 2011.
53. Pacher P, Beckman JS, and Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424, 2007.
54. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, and Abraham E. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279: 7370-7377, 2004.
55. Peter C, Wesselborg S, Herrmann M, and Lauber K. Dangerous attraction: Phagocyte recruitment and danger signals of apoptotic and necrotic cells. Apoptosis 15: 1007-1028, 2010.
56. Pfeiffer S, Schrammel A, Koesling D, Schmidt K, and Mayer B. Molecular actions of a Mn(III)Porphyrin superoxide dismutase mimetic and peroxynitrite scavenger: Reaction with nitric oxide and direct inhibition of NO synthase and soluble guanylyl cyclase. Mol Pharmacol 53: 795-800, 1998.
57. Rabadi MM, Ghaly T, Goligorksy MS, and Ratliff BB. HMGB1 in renal ischemic injury. Am J Physiol Renal Physiol 303: F873-F885, 2012.
58. Rivers JR, Badiei A, and Bhatia M. Hydrogen sulfide as a therapeutic target for inflammation. Expert Opin Ther Targets 16: 439-449, 2012.
59. Sappington PL, Yang R, Yang H, Tracey KJ, Delude RL, and Fink MP. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 123: 790-802, 2002.
60. Scaffidi P, Misteli T, and Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195, 2002.
61. Schierbeck H, Lundback P, Palmblad K, Klevenvall L, Erlandsson-Harris H, Andersson U, and Ottosson L. Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med 17: 1039-1044, 2011.
62. Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E, Apuzzo T, De Marchis F, Pedotti M, Bachi A, Thelen M, Varani L, Mellado M, Proudfoot A, Bianchi ME, and Uguccioni M. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 209: 551-563, 2012.
63. Sharpe MA, Ollosson R, Stewart VC, and Clark JB. Oxidation of nitric oxide by oxomanganese-salen complexes: A new mechanism for cellular protection by superoxide dismutase/ catalase mimetics. Biochem J 366: 97-107, 2002.
64. Silva JP and Coutinho OP. Free radicals in the regulation of damage and cell death-basic mechanisms and prevention. Drug Discov Ther 4: 144-167, 2010.
65. Sims GP, Rowe DC, Rietdijk ST, Herbst R, and Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28: 367-388, 2010.
66. Stamler JS, Singel DJ, and Loscalzo J. Biochemistry of nitric oxide and its redox-Activated forms. Science 258: 1898-1902, 1992.
67. Szabo C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 6: 917-935, 2007.
68. Szabo C, Ischiropoulos H, and Radi R. Peroxynitrite: Biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 6: 662-680, 2007.
69. Takahashi K, Fukushima S, Yamahara K, Yashiro K, Shintani Y, Coppen SR, Salem HK, Brouilette SW, Yacoub MH, and Suzuki K. Modulated inflammation by injection of highmobility group box 1 recovers post-infarction chronically failing heart. Circulation 118: S106-S114, 2008.
70. Tang D, Billiar TA, and Lotze MT. A Janus tale of two active HMGB1 redox states. Mol Med 18: 1360-1362, 2012.
71. Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, Benschop R, Sparvero LJ, Amoscato AA, Tracey KJ, Zeh HJ, and Lotze MT. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 29: 5299-5310, 2010.
72. Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ, 3rd, and Lotze MT. Endogenous HMGB1 regulates autophagy. J Cell Biol 190: 881-892, 2010.
73. Tang D, Kang R, Livesey KM, Zeh HJ, 3rd, and Lotze MT. High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. Antioxid Redox Signal 15: 2185-2195, 2011.
74. Tang D, Kang R, Zeh HJ, 3rd, and Lotze MT. High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal 14: 1315-1335, 2011.
75. Tang D, Loze MT, Zeh HJ, and Kang R. The redox protein HMGB1 regulates cell death and survival in cancer treatment. Autophagy 6: 1181-1183, 2010.
76. Tang D, Shi Y, Kang R, Li T, Xiao W, Wang H, and Xiao X. Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol 81: 741-747, 2007.
77. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S, Nakajima T, Komiya S, and Maruyama I. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 48: 971-981, 2003.
78. Thomas JO and Travers AA. HMG1 and 2, and related 'architectural' DNA-binding proteins. Trends Biochem Sci 26: 167-174, 2001.
79. Trujillo M, Ferrer-Sueta G, and Radi R. Peroxynitrite detoxification and its biologic implications. Antioxid Redox Signal 10: 1607-1620, 2008.
80. Tsuda K, Kikuchi M, Mori K, Waga S, and Yoshida M. Primary structure of non-histone protein HMG1 revealed by the nucleotide sequence. Biochemistry 27: 6159-6163, 1988.
81. Tsung A, Klune JR, Zhang X, Jeyabalan G, Cao Z, Peng X, Stolz DB, Geller DA, Rosengart MR, and Billiar TR. HMGB1 release induced by liver ischemia involves Tolllike receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med 204: 2913-2923, 2007.
82. Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, Czura CJ, Fink MP, and Tracey KJ. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A 99: 12351-12356, 2002.
83. Urbonaviciute V, Furnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, Bianchi ME, Kirschning C, Wagner H, Manfredi AA, Kalden JR, Schett G, Rovere-Querini P, Herrmann M, and Voll RE. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: Im-plications for the pathogenesis of SLE. J Exp Med 205: 3007-3018, 2008.
84. Urbonaviciute V, Meister S, Furnrohr BG, Frey B, Guckel E, Schett G, Herrmann M, and Voll RE. Oxidation of the alarmin high-mobility group box 1 protein (HMGB1) during apoptosis. Autoimmunity 42: 305-307, 2009.
85. Vallance P and Leiper J. Blocking NO synthesis: How, where and why?. Nat Rev Drug Discov 1: 939-950, 2002.
86. Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, De Marchis F, Liu J, Antonelli A, Preti A, Raeli L, Shams SS, Yang H, Varani L, Andersson U, Tracey KJ, Bachi A, Uguccioni M, and Bianchi ME. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 209: 1519-1528, 2012.
87. Volz HC, Kaya Z, Katus HA, and Andrassy M. The role of HMGB1/RAGE in inflammatory cardiomyopathy. Semin Thromb Hemost 36: 185-194, 2010.
88. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, and Tracey KJ. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251, 1999.
89. Whiteman M, Armstrong JS, Chu SH, Jia-Ling S, Wong BS, Cheung NS, Halliwell B, and Moore PK. The novel neuromodulator hydrogen sulfide: An endogenous peroxynitrite 'scavenger'?. J Neurochem 90: 765-768, 2004.
90. Whiteman M, Le Trionnaire S, Chopra M, Fox B, and Whatmore J. Emerging role of hydrogen sulfide in health and disease: Critical appraisal of biomarkers and pharmacological tools. Clin Sci (Lond) 121: 459-488, 2011.
91. Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, Meng Q, Mustafa AK, Mu W, Zhang S, Snyder SH, and Wang R. H2S as a physiologic vasorelaxant: Hypertension in mice with deletion of cystathionine gamma-lyase. Science 322: 587-590, 2008.
92. Yang GL, Zhang LH, Bo JJ, Huo XJ, Chen HG, Cao M, Liu DM, and Huang YR. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol 106: 57-61, 2012.
93. Yang H, Hirooka K, Liu Y, Fujita T, Fukuda K, Nakamutra T, Itano T, Zhang J, Nishibori M, and Shiraga F. Deleterious role of anti-high mobility group box 1 monoclonal antibody in retinal ischemia-reperfusion injury. Curr Eye Res 36: 1037-1046, 2011.
94. Yang H, Lundback P, Ottosson L, Erlandsson-Harris H, Venereau E, Bianchi ME, Al-Abed Y, Andersson U, Tracey KJ, and Antoine DJ. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med 18: 250-259, 2012.
95. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, and Tracey KJ. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 101: 296-301, 2004.
96. Zingarelli B. Ethyl pyruvate: A simple solution?. Crit Care Med 32: 1603-1604, 2004.